InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR How could proposed changes to data protection laws affect research? December 8, 2021 New reports show staff shortages continue to hold back cancer care June 9, 2022 Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and... October 20, 2022 Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer May 24, 2023 Load more HOT NEWS Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... Navigating Your Care During Long-Term Cancer Survivorship Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
